18/10/2017 - 06:17

PharmAust achieves key goal with anti-cancer drug

18/10/2017 - 06:17

Bookmark

Save articles for future reference.

ASX-listed biotech PharmAust has hit several key milestones in the development of its promising anti-cancer drug Monepantel, or MPL as it is commonly known. The company says reformulation of the potential breakthrough anti-cancer substance is progressing well, with its Canadian partner, BRI Pharmaceutical Research, achieving long awaited improvements on taste and dosage capacity.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options